Replies to post #155917 on Biotech Values

[DewDiligence]

Major FoB Collaborations

[New detail for ACT (f/k/a WPI)-AMGN collaboration;
new table entry for Procognia-UTR.]

 
                 Date   Targets   iHub References 
 Catalent-UMN   12/12   Asia      #msg-82556713 
 Merck KGaA-RDY  6/12   oncology  #msg-76359649 
 Daiichi-Coherus 5/12   *         #msg-75397629 
 Fujifilm-Kyowa  3/12   Humira    #msg-73800486 
 ACT-Bioton      2/12   insulin   #msg-74987123 
 ACT-AMGN       12/11   †         #msg-83846381, #msg-70101928 
 BAX-MNTA       12/11   various   #msg-70212854, #msg-70258421 
 Samsung-BIIB   12/11   various   #msg-69629103, #msg-80622249 
 MRK-Hanwha      6/11   Enbrel    #msg-64164954, #msg-64193403  
 MYL-Biocon      6/09   various   #msg-39119393, #msg-72421544  
 TEVA-Lonza      1/09   various   #msg-34930012, #msg-80236315 
 Procognia-UTR   n/a    Humira    #msg-84340976

*Enbrel and Rituxan in selected Asian countries.

†Humira, Remicade, Heceptin, Avastin, Rituxan, Erbitux.